Prosecution Insights
Prosecution Insights
6 pending office actions • 6 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (50%) |
| §102 only | 1 (17%) |
| No statute on record | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEITH, NANCY J | 1 | 74.7% | +43.8% |
| GRABER, JAMES J | 1 | 46.2% | +56.1% |
| FAY, ZOHREH ALEMZADEH | 1 | 51.8% | -6.7% |
| WILSON, MICHAEL C | 1 | 41.7% | +17.6% |
| VYAS, KEYUR ANILKUMAR | 1 | 51.5% | +63.5% |
| RYAN, DOUGLAS CHARLES | 1 | 40.0% | +48.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17378954 | COMPOSITION FOR TREATING LUNG CANCER, PARTICULARLY OF NON-SMALL LUNG CANCERS (NSCLC) | WILSON, MICHAEL C | 81d overdue |
| 17045236 | NOVEL YELLOW FEVER NUCLEIC ACID MOLECULES FOR VACCINATION | VYAS, KEYUR ANILKUMAR | 72d overdue |
| 17620047 | ROTAVIRUS MRNA VACCINE | GRABER, JAMES J | 8d overdue |
| 17576583 | ARTIFICIAL NUCLEIC ACID MOLECULES | LEITH, NANCY J | 30d |
| 16757289 | NOVEL ARTIFICIAL NUCLEIC ACID MOLECULES | RYAN, DOUGLAS CHARLES | 40d |
| Art Unit | Apps |
|---|---|
| 1636 | 1 |
| 1631 | 1 |
| 1617 | 1 |
| 1638 | 1 |
| 1637 | 1 |
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17576583 | ARTIFICIAL NUCLEIC ACID MOLECULES | LEITH, NANCY J | 1636 | Other | Non-Final OA | 30d | Pending | Jan 14, 2022 |
| 17620047 | ROTAVIRUS MRNA VACCINE | GRABER, JAMES J | 1631 | §102 | Final Rejection | 8d overdue | Pending | Dec 16, 2021 |
| 17429182 | CODING RNA ADMINISTERED INTO THE SUPRACHOROIDAL SPACE IN THE TREATMENT OF OPHTHALMIC DISEASES | FAY, ZOHREH ALEMZADEH | 1617 | §103 | Non-Final OA | 73d overdue | Pending | Aug 06, 2021 |
| 17378954 | COMPOSITION FOR TREATING LUNG CANCER, PARTICULARLY OF NON-SMALL LUNG CANCERS (NSCLC) | WILSON, MICHAEL C | 1638 | §103 | Final Rejection | 81d overdue | Pending | Jul 19, 2021 |
| 17045236 | NOVEL YELLOW FEVER NUCLEIC ACID MOLECULES FOR VACCINATION | VYAS, KEYUR ANILKUMAR | 1637 | §103 | Non-Final OA | 72d overdue | Pending | Oct 05, 2020 |
| 16757289 | NOVEL ARTIFICIAL NUCLEIC ACID MOLECULES | RYAN, DOUGLAS CHARLES | 1635 | Other | Final Rejection | 40d | Pending | Apr 17, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial